This clinical trial is focused on studying a condition known as severe community-acquired pneumonia, which is a serious lung infection that people can get outside of a hospital setting. The study is testing a treatment called Trimodulin, which is a solution made from human proteins that help the immune system. This treatment will be compared to a placebo, which looks like the treatment but does not contain the active ingredients. Both Trimodulin and the placebo will be given to patients through an intravenous infusion, meaning they will be administered directly into the bloodstream through a vein.
The purpose of the study is to see if Trimodulin can reduce the number of deaths within 28 days compared to the placebo. Participants in the study are adults who are hospitalized with severe pneumonia. The study will follow these patients over a period of time to monitor their health and recovery. Researchers will look at various outcomes, such as how many patients survive, how their health changes over time, and how long they need to stay in the hospital or intensive care unit.
Throughout the study, doctors will also check for any side effects or reactions to the treatment. The study aims to provide valuable information on whether Trimodulin is a safe and effective treatment for severe pneumonia, potentially offering a new option for patients with this serious condition.
Austria 
Belgium 
Czechia 
France 
Germany 
Hungary 
Ireland 
Romania 
Spain 
